UK Brushes Up No-Deal Brexit Legislation
Executive Summary
Some changes have been made to UK legislation that will aim to ensure the effective operation of the regulatory system once the country leaves the EU. Areas affected include the QPPV, pediatric and orphan medicines, and the reference product for generic approvals.
You may also be interested in...
UK MHRA Looks Beyond Brexit Transition
Now that the UK has left the EU, the UK’s medicines regulator says it will use the rest of this year to work out how best to ensure continuity of drug regulation after the Brexit transition period ends on 31 December.
UK No-Deal Medicines Regulation Under Threat As Brexit Chaos Grows
Draft regulations on medicines and medical devices could get caught up in the chaos that seems about to engulf the UK parliament as opposition MPs attempt to avert a no-deal Brexit.
Brexit Stakes Rise As New UK Prime Minister Takes Over
The UK has a new prime minister in Boris Johnson, who is likely to surround himself with strongly pro-Brexit ministers. The life sciences industry will need to continue lobbying for its interests to be protected in the event of a no-deal exit.